Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SepternaSEPN -1.77%12 EV-to-FCF is 13.34 as of Aug. 08, 2026, which is 1350% above its 10-year median of 0.92. GuruFocus rates SEPN with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 341 Biotechnology companies, Septerna ranks better than 52.79% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Septerna's Enterprise Value is $1,425.97 Mil.
Septerna's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $106.93 Mil. Therefore, Septerna's EV-to-FCF for today is 13.34.
The historical rank and industry rank for Septerna's EV-to-FCF or its related term are showing as below:
SEPN'
s EV-to-FCF Range Over the Past 10 Years
Min: -16.94 Med: 0.92 Max: 14.1
Current: 13.34
During the past 4 years, the highest EV-to-FCF of Septerna was 14.10. The lowest was -16.94. And the median was 0.92.
SEPN's EV-to-FCF is ranked better than 52.79% of 341
companies
in the Biotechnology industry
Industry Median: 15.04
vs SEPN: 13.34
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Septerna's share price for today is $38.83.
Septerna's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.810.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Septerna EV-to-FCF Related Terms
Septerna EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Septerna's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Septerna's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Septerna EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Septerna's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Septerna's EV-to-FCF falls into.
Septerna's current Enterprise Value is $1,425.97 Mil.
Septerna's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $106.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Septerna (SEPN) has a EV-to-FCF of 13.34 as of Aug. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Septerna and its competitors. This is 1350% above median its historical median of 0.92. According to the industry distribution chart, Septerna ranks #161 out of 341 companies in the Biotechnology industry, placing it in the top 47.2%.
Is Septerna's EV-to-FCF too high?
Septerna's current EV-to-FCF of 13.34 is 1350% above median its 10-year median of 0.92. The Biotechnology industry median EV-to-FCF is 15.04. Septerna's value of 13.34 is 11.3% below this industry median. Based on the distribution chart, Septerna ranks #161 out of 341 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Septerna has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Septerna's EV-to-FCF compare to NTLA and AVBP?
According to the Biotechnology industry distribution chart, Septerna ranks #161 out of 341 companies for EV-to-FCF. This puts Septerna in the upper half of its industry. The industry median EV-to-FCF is 15.04. Septerna's value of 13.34 is 11.3% below this benchmark. While the company's 10-year median is 0.92 vs. the industry median of 15.04, Septerna has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.04, based on 341 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Septerna's current EV-to-FCF of 13.34 is 11.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Septerna and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Septerna's current EV-to-FCF is 13.34, which is 1350% above median its own 10-year median of 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Septerna stock overvalued right now?
Septerna (SEPN) has a current EV-to-FCF of 13.34. The current EV-to-FCF is 13.34, which is 1350% above median its 10-year median of 0.92 and 11.3% below the Biotechnology industry median of 15.04. Septerna's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Septerna (SEPN), the current EV-to-FCF is 13.34 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
12GF Score
Get the complete analysis for SEPN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SEPN has been successfully added to your 
